Intercept rollercoaster continues with NASH, PBC updates

Intercept Pharmaceuticals fell 30.1% to $172.59 per share on 7 November after data from the Phase II FLINT clinical trial for obeticholic acid (OCA) were published in The Lancet, but the update provided little new information about the drug's safety and efficacy in non-alcoholic steatohepatitis (NASH).